Evaxion Biotecch (EVAX)
(Delayed Data from NSDQ)
$3.15 USD
-0.15 (-4.57%)
Updated Jul 15, 2024 03:58 PM ET
After-Market: $3.09 -0.06 (-1.88%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EVAX 3.15 -0.15(-4.57%)
Will EVAX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVAX
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
EVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' Now
Other News for EVAX
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
Evaxion Biotech’s Innovative Cancer Vaccine Patent Progress
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
Evaxion receives positive feedback on patent application for vaccine targets
Evaxion Biotech Updates Warrant Exercise Price